These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 26619541)

  • 1. [The Expressions of Somatostatin and Cycloxygenase-2 in Chronic Hepatitis, Hepatic Cirrhosis, Precancerous Lesion and Hepatocellular Carcinoma].
    Xie YM; Li X; Yan LN; Wei B; Wang CH; Tang CW
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Sep; 46(5):710-6. PubMed ID: 26619541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Kwon SH; Jeong SW; Jang JY; Lee JE; Lee SH; Kim SG; Kim YS; Cho YD; Kim HS; Kim BS; Jin SY
    Clin Mol Hepatol; 2012 Sep; 18(3):287-94. PubMed ID: 23091809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 expression in hepatocellular carcinoma, cirrhosis and chronic hepatitis in the United States.
    Pazirandeh S; Khettry U; Gordon FD; Resnick RH; Murray JE; Sheth SG
    Dig Dis Sci; 2007 Jan; 52(1):220-7. PubMed ID: 17160481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of microRNA-16, microRNA-21 and microRNA-101 expression with cyclooxygenase-2 expression and angiogenic factors in cirrhotic and noncirrhotic human hepatocellular carcinoma.
    Zeng W; van den Berg A; Huitema S; Gouw AS; Molema G; de Jong KP
    PLoS One; 2014; 9(4):e95826. PubMed ID: 24759835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration].
    Xie YM; Yan LN; Wei B; Guo MM; Tang CW
    Ai Zheng; 2007 Jul; 26(7):688-92. PubMed ID: 17626741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.
    Reynaert H; Rombouts K; Vandermonde A; Urbain D; Kumar U; Bioulac-Sage P; Pinzani M; Rosenbaum J; Geerts A
    Gut; 2004 Aug; 53(8):1180-9. PubMed ID: 15247189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma.
    Nagata K; Hirono S; Ido A; Kataoka H; Moriuchi A; Shimomura T; Hori T; Hayashi K; Koono M; Kitamura N; Tsubouchi H
    Biochem Biophys Res Commun; 2001 Nov; 289(1):205-11. PubMed ID: 11708800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The expression of hepatitis B virus X protein and cyclooxygenase-2 in hepatitis B virus-related hepatocellular carcinoma: correlation with microangiogenesis and metastasis, and what is the possible mechanism].
    Liu KG; Shao XL; Xie HH; Xu L; Zhao H; Guo ZH; Li L; Liu J
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):831-6. PubMed ID: 21138631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma.
    Nardone G; Romano M; Calabrò A; Pedone PV; de Sio I; Persico M; Budillon G; Bruni CB; Riccio A; Zarrilli R
    Hepatology; 1996 Jun; 23(6):1304-12. PubMed ID: 8675143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocellular carcinoma in cirrhotic patients with transjugular intrahepatic portosystemic shunt: a retrospective case-control study.
    De Santis A; Iegri C; Kondili L; Riggio O; Salvatori FM; Catalano C; Di Martino M; Bassanelli C; Lupo M; Lucatelli P; Attili AF
    Dig Liver Dis; 2014 Aug; 46(8):726-30. PubMed ID: 24893685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Up-Regulation of ninjurin expression in human hepatocellular carcinoma associated with cirrhosis and chronic viral hepatitis.
    Kim JW; Moon AR; Kim JH; Yoon SY; Oh GT; Choe YK; Choe IS
    Mol Cells; 2001 Apr; 11(2):151-7. PubMed ID: 11355694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma.
    Park BC; Huh MH; Seo JH
    J Hepatol; 1995 Mar; 22(3):286-94. PubMed ID: 7608479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of alpha-fetoprotein and albumin genes in human hepatocellular carcinomas: limitations in the application of the genes for targeting human hepatocellular carcinoma in gene therapy.
    Ohguchi S; Nakatsukasa H; Higashi T; Ashida K; Nouso K; Ishizaki M; Hino N; Kobayashi Y; Uematsu S; Tsuji T
    Hepatology; 1998 Feb; 27(2):599-607. PubMed ID: 9462663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA measurements in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Lin HH; Shyu WC; Chen GL; Lin YH; Chen TJ; Liaw YF
    Liver; 1990 Oct; 10(5):313-8. PubMed ID: 2175006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
    Huang Q; Tan Y; Yin P; Ye G; Gao P; Lu X; Wang H; Xu G
    Cancer Res; 2013 Aug; 73(16):4992-5002. PubMed ID: 23824744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver.
    Masaki T; Tokuda M; Yoshida S; Nakai S; Morishita A; Uchida N; Funaki T; Kita Y; Funakoshi F; Nonomura T; Himoto T; Deguchi A; Kimura Y; Izuishi K; Wakabayashi H; Usuki H; Yoshiji H; Watanabe S; Kurokohchi K; Kuriyama S
    Int J Oncol; 2005 Mar; 26(3):661-71. PubMed ID: 15703821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.